Darigabat
Clinical data | |
---|---|
Other names | CVL-865; PF-06372865; PF-6372865 |
Routes of administration | Oral administration |
Drug class | GABAA receptor positive allosteric modulator |
Pharmacokinetic data | |
Metabolism | CYP3A4[1] |
Elimination half-life | 11 hours[1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C22H21FN4O3S |
Molar mass | 440.49 g·mol−1 |
3D model (JSmol) |
|
| |
InChI
|
Darigabat (developmental code names CVL-865, PF-06372865, PF-6372865) is a GABAergic medication which is under development for the treatment of photosensitive epilepsy, focal onset seizures, panic disorder, and other anxiety disorders.[2][3] It was also under development for the treatment of generalized anxiety disorder and chronic lower back pain, but development for these indications was discontinued.[2][3][4] It is taken via oral administration.[2]
Darigabat acts as a GABAA receptor positive allosteric modulator[2][3][5] It is specifically a positive allosteric modulator that selectively targets α2, α3, and α5 subunit-containing GABAA receptors, with minimal functional activity at α1 subunit-containing GABAA receptors.[3][5] A dose of darigabat that achieved more than 80% receptor occupancy showed no somnolence with dose titration, whereas benzodiazepines, which are non-selective GABAA receptor positive allosteric modulators, achieve only 10 to 15% receptor occupancy whilst producing significant or severe somnolence.[3][5] It is theorized that α1 subunit-containing GABAA receptors preferentially mediate sedation, amnesia, and ataxia, whereas α2 and α3 subunit-containing GABAA receptors mediate anxiolysis.[3][5] However, this model has also been questioned.[4] α1 subunit-containing GABAA receptors are said to be completely unaffected by darigabat.[6] The elimination half-life of darigabat is 11 hours and it is metabolized mainly by CYP3A4.[1]
In clinical trials conducted thus far, side effects of darigabat have included dizziness, fatigue, headache, mild-to-moderate somnolence, bradyphrenia (slowness of thought), modest memory impairment, mild cognitive impairment, balance impairment, and feeling abnormal.[3][6] It has been described as well-tolerated.[3][4]
Darigabat was originated by Pfizer and is under development by Cerevel Therapeutics and Pfizer.[2] As of January 2023, it is in phase 2 clinical trials for epilepsy and seizures, phase 1 trials for panic disorder, and preclinical development for anxiety disorders.[2][3] Development for back pain was discontinued due to lack of effectiveness in a phase 2 trial, while development for generalized anxiety disorder was discontinued due to business reasons as well as lack of effectiveness in a phase 2 trial.[3][4][2]
See also
References
- ^ a b c Elkommos S, Mula M (December 2022). "Current and future pharmacotherapy options for drug-resistant epilepsy". Expert Opin Pharmacother. 23 (18): 2023–2034. doi:10.1080/14656566.2022.2128670. PMID 36154780. S2CID 252542159.
- ^ a b c d e f g "Darigabat - Cerevel Therapeutics - AdisInsight".
- ^ a b c d e f g h i j Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, Golani LK, Cook JM, Witkin JM (June 2022). "GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacol Ther. 234: 108035. doi:10.1016/j.pharmthera.2021.108035. PMC 9787737. PMID 34793859.
- ^ a b c d Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, Kivell BM, Knutson DE, Sharmin D, Pandey KP, Mian MY, Cook JM, Cerne R (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacol Biochem Behav. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID 35041859. S2CID 245963990.
- ^ a b c d Quagliato LA, Carta MG, Nardi AE (2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". J Clin Psychopharmacol. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID 36099401. S2CID 252219658.
- ^ a b Janković SM, Dješević M, Janković SV (2021). "Experimental GABA A Receptor Agonists and Allosteric Modulators for the Treatment of Focal Epilepsy". J Exp Pharmacol. 13: 235–244. doi:10.2147/JEP.S242964. PMC 7954424. PMID 33727865.
External links
- Darigabat - AdisInsight
- v
- t
- e
- Brometone
- Butanol
- Chloralodol
- Chlorobutanol (cloretone)
- Ethanol (alcohol) (alcoholic drink)
- Ethchlorvynol
- Isobutanol
- Isopropanol
- Menthol
- Methanol
- Methylpentynol
- Pentanol
- Petrichloral
- Propanol
- tert-Butanol (2M2P)
- tert-Pentanol (2M2B)
- Tribromoethanol
- Trichloroethanol
- Triclofos
- Trifluoroethanol
- (-)-DMBB
- Allobarbital
- Alphenal
- Amobarbital
- Aprobarbital
- Barbexaclone
- Barbital
- Benzobarbital
- Benzylbutylbarbiturate
- Brallobarbital
- Brophebarbital
- Butabarbital/Secbutabarbital
- Butalbital
- Buthalital
- Butobarbital
- Butallylonal
- Carbubarb
- Crotylbarbital
- Cyclobarbital
- Cyclopentobarbital
- Difebarbamate
- Enallylpropymal
- Ethallobarbital
- Eterobarb
- Febarbamate
- Heptabarb
- Heptobarbital
- Hexethal
- Hexobarbital
- Metharbital
- Methitural
- Methohexital
- Methylphenobarbital
- Narcobarbital
- Nealbarbital
- Pentobarbital
- Phenallymal
- Phenobarbital
- Phetharbital
- Primidone
- Probarbital
- Propallylonal
- Propylbarbital
- Proxibarbital
- Reposal
- Secobarbital
- Sigmodal
- Spirobarbital
- Talbutal
- Tetrabamate
- Tetrabarbital
- Thialbarbital
- Thiamylal
- Thiobarbital
- Thiobutabarbital
- Thiopental
- Thiotetrabarbital
- Valofane
- Vinbarbital
- Vinylbital
- 2-Oxoquazepam
- 3-Hydroxyphenazepam
- Adinazolam
- Alprazolam
- Arfendazam
- Avizafone
- Bentazepam
- Bretazenil
- Bromazepam
- Bromazolam
- Brotizolam
- Camazepam
- Carburazepam
- Chlordiazepoxide
- Ciclotizolam
- Cinazepam
- Cinolazepam
- Clazolam
- Climazolam
- Clobazam
- Clonazepam
- Clonazolam
- Cloniprazepam
- Clorazepate
- Clotiazepam
- Cloxazolam
- CP-1414S
- Cyprazepam
- Delorazepam
- Demoxepam
- Diazepam
- Diclazepam
- Dimdazenil
- Doxefazepam
- Elfazepam
- Estazolam
- Ethyl carfluzepate
- Ethyl dirazepate
- Ethyl loflazepate
- Etizolam
- FG-8205
- Fletazepam
- Flubromazepam
- Flubromazolam
- Fludiazepam
- Flunitrazepam
- Flunitrazolam
- Flurazepam
- Flutazolam
- Flutemazepam
- Flutoprazepam
- Fosazepam
- Gidazepam
- Halazepam
- Haloxazolam
- Iclazepam
- Imidazenil
- Irazepine
- Ketazolam
- Lofendazam
- Lopirazepam
- Loprazolam
- Lorazepam
- Lormetazepam
- Meclonazepam
- Medazepam
- Menitrazepam
- Metaclazepam
- Mexazolam
- Midazolam
- Motrazepam
- N-Desalkylflurazepam
- Nifoxipam
- Nimetazepam
- Nitrazepam
- Nitrazepate
- Nitrazolam
- Nordazepam
- Nortetrazepam
- Oxazepam
- Oxazolam
- Phenazepam
- Pinazepam
- Pivoxazepam
- Prazepam
- Premazepam
- Proflazepam
- Pyrazolam
- QH-II-66
- Quazepam
- Reclazepam
- Remimazolam
- Rilmazafone
- Ripazepam
- Ro48-6791
- Ro48-8684
- SH-053-R-CH3-2′F
- Sulazepam
- Temazepam
- Tetrazepam
- Tolufazepam
- Triazolam
- Triflubazam
- Triflunordazepam (Ro5-2904)
- Tuclazepam
- Uldazepam
- Zapizolam
- Zolazepam
- Zomebazam
- 6-Methylapigenin
- Ampelopsin (dihydromyricetin)
- Apigenin
- Baicalein
- Baicalin
- Catechin
- EGC
- EGCG
- Hispidulin
- Linarin
- Luteolin
- Rc-OMe
- Skullcap constituents (e.g., baicalin)
- Wogonin
- 10-Methoxyyangonin
- 11-Methoxyyangonin
- 11-Hydroxyyangonin
- Desmethoxyyangonin
- 11-Methoxy-12-hydroxydehydrokavain
- 7,8-Dihydroyangonin
- Kavain
- 5-Hydroxykavain
- 5,6-Dihydroyangonin
- 7,8-Dihydrokavain
- 5,6,7,8-Tetrahydroyangonin
- 5,6-Dehydromethysticin
- Methysticin
- 7,8-Dihydromethysticin
- Yangonin
- Acecarbromal
- Apronal (apronalide)
- Bromisoval
- Carbromal
- Capuride
- Ectylurea
- Acebrochol
- Allopregnanolone (brexanolone)
- Alfadolone
- Alfaxalone
- 3α-Androstanediol
- Androstenol
- Androsterone
- Certain anabolic-androgenic steroids
- Cholesterol
- DHDOC
- 3α-DHP
- 5α-DHP
- 5β-DHP
- DHT
- Etiocholanolone
- Ganaxolone
- Hydroxydione
- Minaxolone
- ORG-20599
- ORG-21465
- P1-185
- Posovolone
- Pregnanolone (eltanolone)
- Progesterone
- Renanolone
- SAGE-105
- SAGE-324
- SAGE-516
- SAGE-689
- SAGE-872
- Testosterone
- THDOC
- Zuranolone
- Acetone
- Acetophenone
- Acetylglycinamide chloral hydrate
- Aliflurane
- Benzene
- Butane
- Butylene
- Centalun
- Chloral
- Chloral betaine
- Chloral hydrate
- Chloroform
- Cryofluorane
- Desflurane
- Dichloralphenazone
- Dichloromethane
- Diethyl ether
- Enflurane
- Ethyl chloride
- Ethylene
- Fluroxene
- Gasoline
- Halopropane
- Halothane
- Isoflurane
- Kerosine
- Methoxyflurane
- Methoxypropane
- Nitric oxide
- Nitrogen
- Nitrous oxide
- Norflurane
- Paraldehyde
- Propane
- Propylene
- Roflurane
- Sevoflurane
- Synthane
- Teflurane
- Toluene
- Trichloroethane (methyl chloroform)
- Trichloroethylene
- Vinyl ether
- 3-Hydroxybutanal
- α-EMTBL
- AA-29504
- Alogabat
- Avermectins (e.g., ivermectin)
- Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide)
- Carbamazepine
- Chloralose
- Chlormezanone
- Clomethiazole
- Darigabat
- DEABL
- Deuterated etifoxine
- Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine))
- DS2
- Efavirenz
- Etazepine
- Etifoxine
- Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid)
- Fluoxetine
- Flupirtine
- Hopantenic acid
- KRM-II-81
- Lanthanum
- Lavender oil
- Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol)
- Loreclezole
- Menthyl isovalerate (validolum)
- Monastrol
- Niacin
- Niacinamide
- Org 25,435
- Phenytoin
- Propanidid
- Retigabine (ezogabine)
- Safranal
- Seproxetine
- Stiripentol
- Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional)
- Terpenoids (e.g., borneol)
- Topiramate
- Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol)